Fabrazyme Market Report 2026

Fabrazyme Market Overview

• The Fabrazyme market growth in the historic period has been driven by lack of curative options for fabry disease, early success of enzyme replacement therapy • Market expansion is supported by rising awareness of fabry disease, improved genetic screening programs • Growth Driver: Increasing Cases Of Genetic Disorders Are Expected To Drive Growth In The Fabrazyme Market • North America was the largest region in 2025.

What Is Covered Under Fabrazyme Market?

Fabrazyme is a prescription medication used primarily for the treatment of Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. This deficiency leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) in various tissues, which can cause serious health issues, including kidney damage, heart problems, and neurological complications. The main types of fabrazyme are 5 mg/vial and 35 mg/vial. 5 mg/vial refers to fabrazyme supplied in single-dose vials containing 5 milligrams of the active ingredient, agalsidase beta. The applications are hospitals and drug stores, and the end users include pediatric and adult.

What Is The Fabrazyme Market Growth Forecast?

The fabrazyme market size is expected to see rapid growth in the next few years. It will grow to $2.35 million in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to rising awareness of fabry disease, improved genetic screening programs, expansion of specialty rare disease clinics, long term treatment adherence focus, continued investment in orphan drug development. Major trends in the forecast period include growing use of enzyme replacement therapies, increased focus on rare genetic disease management, expansion of long term fabry disease treatment, rising emphasis on early diagnosis and intervention, improved multisystem disease monitoring approaches.

What Are The Drivers Of The Fabrazyme Market?

Increasing cases of genetic disorders are expected to propel the growth of the fabrazyme market going forward. Genetic disorders refer to health conditions caused by abnormalities in an individual's genetic material. Increasing cases of genetic disorders are primarily due to advanced diagnostic technologies identifying more cases and factors such as delayed parenthood, environmental influences, and lifestyle changes contributing to genetic mutations. Fabrazyme, an enzyme replacement therapy, helps individuals with Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, by providing the missing enzyme to break down certain lipids that accumulate in the body, thus reducing the risk of organ damage, alleviating symptoms, and improving overall quality of life. For instance, in March 2024, according to Gene People, a UK-based registered charity, in the UK, over 6,000 genetic conditions are diagnosed, affecting approximately 1 in 25 children, which results in around 30,000 new diagnoses each year, and more than 2.4 million individuals currently live with a genetic condition. Therefore, increasing cases of genetic disorders are driving the Fabrazyme industry. The rising healthcare expenditure is expected to propel the growth of the Fabrazyme market going forward. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. Rising healthcare expenditure is due to an ageing population, chronic diseases, higher service prices, increased demand, technological advancements, rising drug costs, the COVID-19 impact, medical inflation, and income polarization. Fabrazyme addresses the underlying causes of Fabry disease through enzyme replacement therapy that receives support from healthcare expenditure as it enables better disease management, reduces the need for costly emergency interventions and long-term treatments, and ultimately leads to improved patient outcomes, thereby justifying its investment in the healthcare system. For instance, in April 2025, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending rose by 6.5% in nominal terms from 2023 to 2024, and by 2.4% in real terms after accounting for inflation. Therefore, the rising healthcare expenditure is driving the growth Fabrazyme industry. Rising personalized medicine is expected to propel the growth of the fabrazyme market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Fabrazyme provides enzyme replacement therapy for individuals with Fabry disease, supports personalized medicine by tailoring treatment to the specific genetic and metabolic needs of patients, enhancing therapeutic efficacy, improving clinical outcomes, and promoting individualized care strategies that address the unique aspects of each patient's condition. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, rising personalized medicine drives the fabrazyme industry.

Key Players In The Global Fabrazyme Market

Major companies operating in the fabrazyme market are Sanofi S.A., JCR Pharmaceuticals, mAbxience

What Defines the Fabrazyme Market?

The fabrazyme market consists of sales of the enzyme replacement therapy (ERT) known as Fabrazyme (agalsidase beta), Replagal (agalsidase alpha), Oral Chaperone Therapies, Substrate Reduction Therapies (SRT). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Fabrazyme Market Report 2026?

The fabrazyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fabrazyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.